Will Kyle Bass’s Drug Patent Gambit Pay Off? He’ll Soon Find Out
This article is for subscribers only.
Hedge-fund manager Kyle Bass has been accusing drugmakers all year of misusing patents to reap “monopoly profits” for medicines, saying he wants to cash in by getting their patents tossed.
Next week, he may learn if his tactic can win.